Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation

Journal of Heart and Lung Transplantation

Volumn 18, Issue 7, 1999, Pages 693-700

  Sartori, Teresa Maria ^a   Maurizio, Patrassi Giovanni ^a   Sara, Pontarollo ^a   Ugolino, Livi ^b   Annalisa, Angelini ^b   Panagiotis, Theodoridis ^a   Massimo, Fioretti ^a   Antonio, Girolami ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BLOOD CLOTTING FACTOR 7; CYCLOSPORIN A; FIBRINOGEN; STEROID; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; ANTICOAGULATION; ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HEART MUSCLE; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; MALE; MICROTHROMBUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK FACTOR; STEROID THERAPY; THROMBOEMBOLISM;

AZATHIOPRINE; BIOPSY; CORONARY ARTERIOSCLEROSIS; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYSIS; GLUCOCORTICOIDS; HEART DISEASES; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYOCARDIUM; POSTOPERATIVE CARE; PREDNISONE; THROMBOSIS; TIME FACTORS;

EID: 0032773403     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(99)00021-2     Document Type: Article

References (48)

1. Samama M. Hypofibrinolysis and venous thrombosis. Neri Serneri G.G., Gensini G.F., Abbate R., Prisco D. Thrombosis: an update. 1992;165-176 Scientific Press, Florence.
2. Sartori M.T., Patrassi G.M., Theodoridis P., Perin A., Pietrogrande F., Girolami A. Heterozygous Type I plasminogen deficiency is associated with an increased risk for thrombosis a statistical analysis in 20 kindreds . Blood Coag Fibrinol. 5:1994;889-893.
3. Patrassi G.M., Sartori M.T., Viero M., Boscaro M., Boeri G., Girolami A. Venous thrombosis and tissue plasminogen activator release deficiency a family study . Blood Coag Fibrinol. 2:1991;231-235.
4. Patrassi G.M., Sartori M.T., Saggiorato G., Boeri G., Girolami A. Familial thrombophilia associated with high levels of plasminogen activator inhibitor. Fibrinolysis. 6:1992;99-103.
5. Hamsten A., Wiman B., de Faire U., Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 313:1985;1557-1563.
6. Cortellaro M., Boschetti C., Colfrancesco E., et al. The PLAT study hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients - principal results . Atheroscler Thromb. 12:1992;1063-1070.
7. Jansson J.H., Nilsson T.K., Olofsson B.O. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J. 12:1991;157-161.
8. EACAT Angina Pectoris Study baseline associations of haemostatic factors with extent of coronary atherosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography . Eur Heart J. 14:1993;8-17.
9. Thompson S.G., Kienast J., Pyke S.D.M., Haverkate F., van de Loo J.C.W. Hemostatic factors and risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 332:1995;635-641.
10. Gao S.Z., Schroeder J.S., Hunt S.A., Billingham M.E., Valantine A.A., Stinson E.B. Acute myocardial infarction in cardiac transplant recipients. Am J Cardiol. 64:1989;1093-1097.
11. Olivari M.T., Kubo S.H., Braunlin E.A., Bolman R.M., Ring S.W. Five-year experience with triple-drug immunosuppressive therapy in cardiac transplantation. Circulation. 82:1990;276-280.
12. Miller L.W. Transplant coronary artery disease. J Heart Lung Transplant. 11:1992;S1-S4.
13. de Lorgeril M., Loire R., Guidollet J., Boissonnat P., Dureau G., Renaud S. Accelerated coronary artery disease after heart transplantation the role of enhanced platelet aggregation and thrombosis . J Int Med. 233:1993;343-350.
14. Forrat R., Ferrera R., Boissonnat P., et al. High prevalence of thromboembolic complications in heart transplant recipients. Which preventive strategy? Transplantation. 61:1996;757-762.
15. Labarrere C.A., Pitts D., Halbrook H., Faulk W.P. Tissue plasminogen activator, plasminogen activator inhibitor-1, and fibrin as indexes of clinical course in cardiac allograft recipients. An immunocytochemical study. Circulation. 89:1994;1599-1608.
16. Labarrere C.A., Pitts D., Nelson D.R., Faulk W.P. Vascular tissue plasminogen activator and the development of coronary artery disease in heart transplant recipients. N Engl J Med. 333:1995;1111-1116.
17. Vanrenterghem Y., Roels L., Lerut T., et al. Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients. Lancet. 1:1985;999-1002.
18. Neidl G.H., Rocchi G., Imberti L., et al. Effect of cyclosporine A on prostacyclin release by vascular tissue. Thromb Res. 32:1983;373-379.
19. Levi M., Wilmink J., Büller H.R., Surachno J., Ten Cate J.W. Impaired fibrinolysis in cyclosporine-treated renal transplant patients. Transplantation. 54:1992;978-983.
20. Huser H., Lammie B., Landmann J., et al. Von Willebrand factor and factor VIII in renal transplant recipients under immunosuppression with cyclosporine and steroids. Clin Nephrol. 34:1990;214-222.
21. Leitha T., Graninger W., Zazgornik J. Cyclosporine A does not increase the frequency of thromboembolic events. Transplant Proc. 20:1988;436-438.
22. Jones R.M., Murie J.A., Ting A., et al. Renal vascular thrombosis of cadaveric renal allograft in patients receiving cyclosporin, azathioprine and prednisone triple therapy. Clin Transplant. 2:1988;122-126.
23. First M.R., Smith R.D., Weiss M.A., et al. Cyclosporine-associated glomerular and arteriolar thrombosis following renal transplantation. Transplant Proc. 21:1989;1567-1570.
24. Ozsoylu S., Strauss H.S., Diamond L.K. Effects of corticosteroids on coagulation of the blood. Nature. 195:1962;1214-1215.
25. Dal Bo Zanon R., Fornasiero L., Boscaro M., Cappellato G., Fabris F., Girolami A. Increased factor VIII associated activities in Cushing's Syndrome a probable hypercoagulable state . Thromb Haemostas. 47:1982;116-117.
26. Patrassi G.M., Dal Bo Zanon R., Boscaro M., Martinelli S., Girolami A. Further studies on hypercoagulable state of patients with Cushing's syndrome. Thromb Haemostas. 54:1985;518-520.
27. Patrassi G.M., Sartori M.T., Viero M.L., Scarano L., Boscaro M., Girolami A. The fibrinolytic potential in patients with Cushing's disease a clue to their hypercoagulable state . Blood Coag Fibrinol. 3:1992;789-793.
28. Patrassi G.M., Sartori M.T., Rigotti P., et al. Reduced fibrinolytic potential one year after kidney transplantation relationship to long-term steroid treatment . Transplantation. 59:1995;1416-1420.
29. Patrassi G.M., Sartori M.T., Rigotti P., et al. Coagulation and fibrinolysis during the first year of immunosuppressive treatment in renal transplantation correspondence between hypercoagulable state and steroid therapy . Clin Appl Thrombosis Hemostasis. 1:1995;277-282.
30. Rånby M., Sundell I.B., Nilsson T.K. Blood collection in strong acid citrate anticoagulant used in a study of dietary influence on basal t-PA activity. Thromb Haemostas. 62:1989;917-922.
31. Becker U., Bartl K., Wahlefeld A.W. A functional photometric assay for plasma fibrinogen. Thromb Res. 35:1984;475-484.
32. Girolami A., Molaro A., Lazzarini M., Scarpa R., Brunetti A. A new congenital haemorrhagic condition due to the presence of abnormal factor X (Factor X Friuli) study of a large kindred . Br J Haematol. 19:1970;179-192.
33. Ness P.M., Perkins H.A. A simple enzyme-immunoassay (EIA) test for factor VIII-related antigen (VIII-AGN). Thromb Haemostas. 42:1979;848-854.
34. Cliffton E.E., Cannamela D.A. Fibrinolytic and proteolytic activity of human plasminogen prepared from fraction III of human plasma. J Appl Physiol. 6:1953;42-47.
35. Holvoet P., Cleemput H., Collen D. Assay of human tissue plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemostas. 54:1985;684-687.
36. Wiman B., Mellbring G., Rånby M. Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. Clin Chem Acta. 127:1983;279-288.
37. Declerck P.J., Alessi M.C., Verstreken M., Kruithof E.K.O., Juan-Vague, I, Collen D. Measurement of plasminogen activator inhibitor 1 in biological fluids with a murine monoclonal antibody-based enzyme-linked immunoassay. Blood. 71:1988;220-225.
38. Erikson E., Rånby M., Gyrender E., Risberg B. Determination of plasminogen activator inhibitor in plasma using t-PA and chromogenic single point poly-D-lysine stimulated assay. Thromb Res. 50:1988;91-101.
39. Patrassi G.M., Sartori M.T., Livi U., et al. Impairment of fibrinolytic potential in long-term steroid treatment after heart transplantation. Transplantation. 64:1997;1610-1614.
40. van Meijer M., Pannekoek H. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis an update . Fibrinolysis. 9:1995;263-276.
41. Wiman B. Plasminogen activator inhibitor 1 (PAI-1) in plasma its role in thrombotic disease . Thromb Haemostas. 74:1995;71-76.
42. Rocha E., Paramo J.A. The relationship between impaired fibrinolysis and coronary heart disease a role for PAI-1 . Fibrinolysis. 8:1994;294-303.
43. Kendall T.J., Wilson J.E., Radio S.J. Cytomegalovirus and other Herpesviruses do they have a role in the development of accelerated coronary arterial disease in human heart allograft? J Heart Lung Transplant. 11:1992;S14-S20.
44. Johnson M.R. Transplant coronary disease non immunologic risk factors . J Heart Lung Transplant. 11:1992;S124-SS32.
45. de Lorgeril M, Dureau G., Boissonnat P. Platelet function and composition in heart transplant recipients compared with nontransplanted coronary patients. Arterioscler Thromb. 12:1992;220-230.
46. Livi U., Luciani G.B., Boffa G.M., et al. Clinical results of steroid-free induction immunosuppression after heart transplantation. Ann Thorac Surg. 55:1993;1160-1165.
47. Labarrere C.A., Nelson D.R., Faulk W.P. Myocardial fibrin deposits in the first month after transplantation predict subsequent coronary artery disease and graft failure in cardiac allograft recipients. Am J Med. 105:1998;207-213.
48. Hunt B.J., Segal H., Yacoub M. Hemostatic changes in heart transplant recipients and their relationship to accelerated coronary sclerosis. Transplantation. 55:1993;309-315.